The development of effective therapeutics targeting PI3Kδ requires a careful balance between high enzymatic potency, isoform selectivity, cellular activity, and favorable pharmacokinetic (PK) properties. In our ongoing effort to advance a novel isoindolinone-based inhibitor series, we focused on refining molecular features to overcome limitations observed in earlier analogs—particularly poor permeability, high polarity, and suboptimal PK profiles. This study details the strategic optimization of the affinity and selectivity regions to achieve compounds with improved drug-like characteristics while maintaining exceptional target engagement.
Initial SAR studies revealed that the aryl-sulfonamide group, although critical for potency, contributed significantly to high polar surface area (PSA > 110 Ų), which correlated with poor in vitro–in vivo correlation and reduced membrane permeability. Compounds with PSA values above this threshold consistently exhibited low oral bioavailability and high clearance in preclinical models. To address this, we prioritized replacements that preserved key interactions while reducing polarity. A series of non-sulfonamide bioisosteres were synthesized, including heterocyclic ethers, cyclic amines, and amides, each designed to maintain electrostatic or hydrogen-bonding potential with Lys779 without introducing excessive polarity.
Among the new scaffolds, compound 32 (R = morpholine derivative) emerged as a standout candidate. It displayed an excellent half-life in Wistar Han rats (t₁/₂ = 1.5 h), moderate clearance (Clₚ = 15.8 mL/min/kg), and good volume of distribution (Vd = 1.6 L/kg), suggesting favorable tissue penetration and sustained exposure. Despite a moderate IC₅₀ of 207 nM in the whole blood assay, its IV PK profile was among the most promising in the series. Similarly, compound 34 demonstrated prolonged half-life (t₁/₂ = 3.7 h) and acceptable oral bioavailability (F% = 35%), indicating potential for once-daily dosing regimens.
Parallel efforts focused on enhancing interactions within the Trp760 “shelf” region—a key determinant of selectivity. We introduced bulky, planar substituents such as substituted phenyl and fused heterocycles capable of π-stacking with Trp760. Compound 28, featuring a morpholine-substituted aryl group, showed optimal stacking geometry and achieved potent inhibition (IC₅₀ = 1.4 nM) with >100-fold selectivity over other PI3K isoforms. X-ray crystallography confirmed the morpholine moiety engaged in van der Waals contacts with Trp760 and maintained a stable orientation within the pocket.
Further optimization targeted the affinity region, where we explored diverse aryl groups bearing hydrogen bond donors and acceptors. Aryl-sulfonamides remained highly potent but were avoided due to their physicochemical liabilities. Instead, we identified a pyrrolidine-linked ether (compound 26) that offered a favorable balance of low PSA (149 Ų), high Papp (32.NCOA4 Antibody Autophagy 1 × 10⁻⁶ cm/s), and strong cellular activity (CysLT IC₅₀ = 22 nM).487-52-5 supplier Its metabolic stability was also superior, likely due to reduced susceptibility to oxidative metabolism compared to sulfonamide-containing analogs.PMID:34779007
In vivo PK evaluation confirmed the benefits of these structural changes. Compounds 25–28 exhibited significantly improved clearance profiles and longer half-lives than early leads. Notably, compound 28 demonstrated robust efficacy in a murine model of inflammation, with plasma concentrations exceeding the IC₅₀ for over 6 hours post-dose.
These findings highlight a successful strategy: replacing highly polar functional groups with sterically compatible, less hydrophilic alternatives that retain essential binding interactions. By decoupling potency from high polarity, we achieved a clear progression toward a viable clinical candidate. The integration of structural data, computational modeling, and iterative SAR has enabled the identification of lead compounds with optimized pharmacological profiles—representing a significant step forward in the development of next-generation PI3Kδ inhibitors.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
